

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

Assignment ID: PATI154190

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Markman Biologics Corporation	04/05/2024
RECEIVING PARTY DATA	
Company Name:	CellTherX
Street Address:	2929 Carlisle Street
Internal Address:	Suite 170
City:	Dallas
State/Country:	TEXAS
Postal Code:	75204
PROPERTY NUMBERS Total: 13	
Property Type	Number
Application Number:	61331805
Application Number:	62805032
Application Number:	17146305
Application Number:	18335344
Application Number:	18529947
Patent Number:	8858647
Patent Number:	9050177
Patent Number:	9622845
Patent Number:	10285795
Patent Number:	11701213
Patent Number:	11246697
Patent Number:	11877921
PCT Number:	pctus1957005
CORRESPONDENCE DATA	
Fax Number:	7023824805
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	7023824804
Email:	sweide@weidemiller.com

Correspondent Name:	Randal Scott Weide
Address Line 1:	10655 Park Run Drive
Address Line 2:	Suite 100
Address Line 4:	Las Vegas, NEVADA 89144

ATTORNEY DOCKET NUMBER:	MARKMN.0024G
--------------------------------	--------------

NAME OF SUBMITTER:	Randal Weide
---------------------------	--------------

SIGNATURE:	Randal Weide
-------------------	--------------

DATE SIGNED:	04/09/2024
---------------------	------------

Total Attachments: 5

source=oly-3540 MBC Assignment of Patents - Fully Signed#page1.tif

source=oly-3540 MBC Assignment of Patents - Fully Signed#page2.tif

source=oly-3540 MBC Assignment of Patents - Fully Signed#page3.tif

source=oly-3540 MBC Assignment of Patents - Fully Signed#page4.tif

source=oly-3540 MBC Assignment of Patents - Fully Signed#page5.tif

ASSIGNMENT

WHEREAS, Markman Biologics Corporation (hereinafter "ASSIGNOR"), a Nevada corporation, is the owner of the patents and patent applications ("Patents and Applications") and the inventions associated therewith ("Inventions") as identified in Exhibit A attached hereto;

AND WHEREAS, CellTherX Corp (hereinafter "ASSIGNEE"), a Texas corporation, with its principal place of business at 2929 Carlisle St., Suite 170, Dallas, TX 75204, has purchased or otherwise obtained all entire right, title, and interest in and to the Patents and Applications and the Inventions from Markman Biologics Corporation via Asset Purchase Agreement between Assignor, as the seller, and Assignee, as the purchaser, dated this date ("Purchase Agreement");

NOW, THEREFORE, for good and valuable consideration associated with the closing of the Purchase Agreement, the receipt of which is hereby acknowledged, ASSIGNOR does hereby acknowledge that it has sold, assigned, transferred and set over, and by these presents does hereby sell, assign, transfer and set over, unto the ASSIGNEE, its successors, legal representatives and assigns, the entire right, title, and interest throughout the world in, to and under the Inventions, and the Patents and Applications and all divisions, renewals and continuations thereof, and all Letters Patent of the United States which may be granted thereon and all reissues and extensions thereof, and all rights of priority under International Conventions and applications for Letters Patent which may hereafter be filed for the Inventions in any country or countries foreign to the United States, and all Letters Patent which may be granted for the Inventions in any country or countries foreign to the United States and all extensions, renewals and reissues thereof and all actions for infringement and damages thereof that exist now or in the future; and ASSIGNOR hereby authorizes and requests the Commissioner of Patents of the United States, and any Official of any country or countries foreign to the United States, whose duty it is to issue patents on applications as aforesaid, to issue all Letters Patent for the Inventions to the ASSIGNEE, its successors, legal representatives and assigns, in accordance with the terms of this instrument.

AND ASSIGNOR HEREBY covenants and agrees that it will communicate to the ASSIGNEE, its successors, legal representatives and assigns, any facts known to it respecting the Inventions, and testify in any legal proceeding, sign all lawful papers, execute all divisional, continuing and reissue applications, make all rightful oaths and generally do everything possible to aid the ASSIGNEE, its successors, legal representatives and assigns, to obtain and enforce proper patent protection for the Inventions in all countries.

This Assignment has been executed effective as of April 5, 2024.

Markman Biologics Corporation
a Nevada corporation

DocuSigned by:
By: Mike Drake
10F86486B26B4D0...
Jay M. Drake
President

EXHIBIT A

REFERENCE NUMBER	TITLE	FILED/ ISSUED	APPLICATION/ PATENT NO.	STATUS
MARKMN.0008P	METHOD AND APPARATUS FOR A PROCESS CREATING AN INTERNAL TISSUE GRAFT FOR ANIMAL AND HUMAN RECONSTRUCTIVE PURPOSES	05/05/10 05/04/11 10/14/14	US 61/331,805 US 13/101,022 US 8,858,647	ISSUED
MARKMN.0012P	METHOD AND APPARATUS FOR A PROCESS CREATING AN INTERNAL TISSUE GRAFT FOR ANIMAL AND HUMAN RECONSTRUCTIVE PURPOSES	11/28/12 06/09/15	US 13/687,082 US 9,050,177	ISSUED
MARKMN.0015P	METHOD AND APPARATUS FOR CREATING A RECONSTRUCTIVE GRAFT	04/03/15 04/18/17	US 14/678,188 US 9,622,845	ISSUED
MARKMN.0016P	METHOD AND APPARATUS FOR CREATING A RECONSTRUCTIVE GRAFT	04/14/17 05/14/19	US 15/487,585 US 10,285,795	ISSUED

REFERENCE NUMBER	TITLE	FILED/ ISSUED	APPLICATION/ PATENT NO.	STATUS
MARKMN.0017P	METHOD AND APPARATUS FOR CREATING A RECONSTRUCTIVE GRAFT	02/13/19 10/18/19 07/06/23	US 62/805,032 US 16/657,124 US 11,701,213	ISSUED
MARKMN.0018P	METHOD AND APPARATUS FOR CREATING A RECONSTRUCTIVE GRAFT	05/13/19 02/15/22	US 16/410,167 US 11,246,697	ISSUED
MARKMN.0019P	METHOD AND APPARATUS FOR CREATING A MODIFIED TISSUE GRAFT	10/18/19	PCT/US19/57005	CLOSED
MARKMN.0020P	METHOD AND APPARATUS FOR CREATING A MODIFIED TISSUE GRAFT	03/26/20 01/03/24	US 16/831,169 US 11,877,921	ISSUED
MARKMN.0022P	METHOD AND APPARATUS FOR CREATING A MODIFIED TISSUE GRAFT	01/11/21	US 17/146,305	PENDING

REFERENCE NUMBER	TITLE	FILED/ ISSUED	APPLICATION/ PATENT NO.	STATUS
MARKMN.0023P	MODIFIED TISSUE GRAFT AND METHODS AND APPARATUS FOR CREATING A MODIFIED TISSUE GRAFT	03/17/21	PCT/US2021/22691	CLOSED
MARKMN.0031P	METHOD AND DEVICE FOR CREATING A MODIFIED DERMAL/COMPACT FASCIAL TISSUE GRAFT	08/26/21	US 63/237,247	CLOSED
MARKMN.0033P	METHOD AND APPARATUS FOR CREATING A RECONSTRUCTIVE GRAFT	06/15/23	US 18/335344	PENDING
MARKMN.0034P	MODIFIED TISSUE GRAFT AND METHODS AND APPARATUS FOR CREATING A MODIFIED TISSUE GRAFT	03/17/22	AU 2021242217	PENDING

REFERENCE NUMBER	TITLE	FILED/ ISSUED	APPLICATION/ PATENT NO.	STATUS
MARKMN.0035P	MODIFIED TISSUE GRAFT AND METHODS AND APPARATUS FOR CREATING A MODIFIED TISUE GRAFT	03/17/22	CN 115916109	PENDING
MARKMN.0036P	MODIFIED TISSUE GRAFT AND METHODS AND APPARATUS FOR CREATING A MODIFIED TISSUE GRAFT	03/17/22	EP 4125711	PENDING
MARKMN.0037P	MODIFIED TISSUE GRAFT AND METHODS AND APPARATUS FOR CREATING A MODIFIED TISSUE GRAFT	12/05/23	US 18/529,947	PENDING